Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of trilobatin to preparation of anti-HIV virus infection medicines

A virus infection, trelobatin pharmaceutical technology, applied in the field of medicine, to achieve the effect of wide source, long application history, high use value and safety

Inactive Publication Date: 2018-08-10
SOUTHERN MEDICAL UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No studies have shown that trelobatin has anti-HIV infection activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trilobatin to preparation of anti-HIV virus infection medicines
  • Application of trilobatin to preparation of anti-HIV virus infection medicines
  • Application of trilobatin to preparation of anti-HIV virus infection medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] The present invention will be further described below in conjunction with experiments, but the protection scope of the present invention is not limited thereto.

[0026] Experiment 1: In vitro cloned virus infection model to detect the inhibitory effect of trilobatin on HIV cloned virus

[0027] experimental method:

[0028] 1) Gradual dilution of trilobatin, with HIV-1 SF162 , HIV-1 NL4-3 and HIV-1 81A and NL4-3 Equal volumes of the virus solution were mixed and co-incubated for 30 minutes, then added to the pre-inoculated TZM-b1 cell culture plate, and the virus control well and the cell blank control well were set;

[0029] 2) 48 hours after virus infection, the expression of luciferase in TZM-b1 cells was detected with a luciferase detection kit.

[0030] Experimental results such as figure 1 As shown, trilobatin can dose-dependently inhibit the activity of three HIV infectious clones, against HIV-1 SF162 , HIV-1 NL4-3 and HIV-1 81A and NL4-3 virus IC 50T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of trilobatin to preparation of anti-HIV virus infection medicines. According to researches, the trilobatin has broad-spectrum anti-HIV-1 activity and low cytotoxicity, and a possible mechanism includes that the trilobatin is capable of specifically targeting at a gp41 N-terminal repeat sequence area to further inhibit HIV entering. The trilobatin is expected tobe developed into excellent anti-HIV small molecule entering inhabitants.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of trilobatin in the preparation of anti-HIV virus infection drugs. Background technique [0002] AIDS (Acquired Immunodeficiency Syndrome, AIDS), also known as Acquired Immunodeficiency Syndrome, is a serious single-cause disease caused by Human Immunodeficiency Virus (Human Immunodeficiency Virus, HIV) infection. As of 2016, about 36.7 million people were infected with HIV worldwide, and 1 million people died of AIDS and related diseases. AIDS mainly includes the following three transmission routes: blood transmission, sexual transmission and vertical transmission from mother to child. Among them, sexual transmission between homosexuals and heterosexuals has become the most important way of AIDS transmission, with a proportion of 80%, and even as high as 90% in some African countries. At present, AIDS has become the largest infectious disease in human beings, seriously...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7034A61P31/18
CPCA61K31/7034
Inventor 李琳殷淑文赖芳圆梁太珍刘叔文
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com